about-me variable
BioReperia invites you to their event

Recapitulating patient tumor complexity, heterogeneity and drug responses in 5-days using ZTX models

About this event


Something smells fishy: Removing doubts – Zebrafish an exceptional translational in-vivo tool for drug development and personalized medicine in cancer

Zebrafish has long been used by academic researchers to reveal molecular mechanisms involved in disease development and treatment. As a tool for cancer research, tumors transplanted to zebrafish embryos, so-called zebrafish tumor xenograft (ZTX) models, are rapidly gaining popularity. This remarkable and diverse in vivo platform has recently been revealed to have diagnostic potential by predicting patient treatment outcome and can therefore be used for precision medicine within oncology. The ZTX platform is also useful for pre-clinical drug development including lead optimization, target validation, immune-oncology, patient stratification, companion diagnostics, and so much more. In the five webinars comprising this webinar series, BioReperia will introduce the latest research based on ZTX models and their applications within drug development and personalized medicine. We will highlight the benefits and potential pitfalls of using ZTX models, and how they can synergize with other cancer model systems or diagnostic tests.

During these five consecutive months from September to January BioReperia is hosting a webinar series in five parts. Please join our webinars by registering for each individual session here, or when they are published on our LinkedIn page and website.

Webinar language: English


Part 1: 21 September 5 pm CEST

Part 2: 19 October 5 pm CEST

Part 3: 16 November 5 pm CEST

Part 4: TBA

Part 5: TBA

This session

Part 1

In this live webinar, Dr Vildevall will talk about how patient derived xenograft (PDX) models can be established in zebrafish, and how such studies have helped accelerate and de-risk late pre-clinical drug development projects. Tumor tissues from patients, implanted and expanded in immunocompromised mice, have been in used by researchers and the Pharma industry to understand how cancer drugs or disease mechanisms work before continuing to clinical trials. Such mouse PDX models are however laborious and therefore costly, and generally require a few to several months before results can be obtained. Recently, zebrafish-PDX models have been established based on bio-banked PDX-tissues and demonstrated the same response to targeted and untargeted cancer drugs as the corresponding mouse-PDX models – however with results being delivered in only 5 days.

Join this live session to find out more about how zebrafish PDX models are generated and utilized, and how they may synergize with mouse-PDX models to accelerate and de-risk late pre-clinical drug development.


Malin Vildevall, PhD

BioReperia, CSO

Hosted by

  • Team member
    MV T
    Malin Vildevall MSL @ BioReperia

  • Guest speaker
    Malin Vildevall CSO @ BioReperia

  • Guest speaker
    Lasse Jensen Co-founder, CTO @ BioReperia


We are a contract research organization (CRO) that increase the speed for your pre-clinical drug discovery.